NCT00534638View on ClinicalTrials.gov

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

PHASE4CompletedINTERVENTIONAL
Enrollment

34,412

Participants

Timeline

Start Date

October 4, 2007

Primary Completion Date

December 17, 2014

Study Completion Date

December 17, 2014

Conditions
Infections, Papillomavirus
Interventions
BIOLOGICAL

Cervarix

Intramuscular injection, 3 doses

BIOLOGICAL

Engerix-B

Intramuscular injection, 3 doses

Trial Locations (6)

15110

GSK Investigational Site, Lahti

20100

GSK Investigational Site, Turku

26100

GSK Investigational Site, Rauma

33100

GSK Investigational Site, Tampere

48100

GSK Investigational Site, Kotka

70100

GSK Investigational Site, Kuopio

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00534638 - Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents | Biotech Hunter | Biotech Hunter